List of Studies ( Metabolite:Acetoin)
Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
---|---|---|---|---|---|---|---|
ST002316 | AN003783 | Differential requirements for mitochondrial electron transport chain components in the adult murine liver - Untargeted Metabolomics (qTOF) | Liver | Mouse | Metabolic syndrome | The University of Texas Southwestern Medical Center at Dallas | area |
ST002113 | AN003460 | Metabolomic analyses redefine the biological classification of pancreatic cancer: From clinical stage to metabolic subtype | Blood | Human | Cancer | Xiamen University | area under peak |
ST002697 | AN004371 | Employing Hindlimb Unloading Model for The Identification of Serum Biomarkers Associated with Cardiovascular and Skeletal Muscle Deconditioning. | Blood | Mouse | Musculoskeletal system disease | Sharjah Institute for Medical Research | AU |
ST002731 | AN004428 | Untargeted Multi-Omics of LNCaP Cell-line Treated with Novel DNA Minor Groove Binder and /or Doxorubicin Using Mass-Spectrometry | LNCaP cells | Human | Cancer | Sharjah Institute for Medical Research | AU |
ST002755 | AN004472 | Metabolomics Profiling of the Antiproliferative, Anti-migratory and Anti-invasive Potential of Amlodipine in Lung Cancer Cells | Lung | Human | Cancer | Sharjah Institute for Medical Research | AU |
ST002976 | AN004886 | Metabolomics Insights into Doxorubicin and 5-Fluorouracil Combination Therapy in Triple-Negative Breast Cancer: A Xenograft Model Study (Part 2) | Blood | Mouse | Cancer | Sharjah Institute for Medical Research | AU |
ST003029 | AN004966 | Estrogen-mediated inhibition of purine metabolism and cell cycle arrest as a novel therapeutic approach in colorectal cancer cells | Colorectal Cancer Cells | Human | Cancer | Sharjah Institute for Medical Research | AU |
ST003146 | AN005162 | Exploring The Impact of Two Novel DNA Minor Groove Binders on HCT-116 Cells: A Comprehensive Multi-Omics Analysis Using Mass Spectrometry | Cultured cells | Human | Cancer | Sharjah Institute for Medical Research | AU |
ST003201 | AN005251 | Molecular signatures of xenograft colon cancer models treated with topotecan: A Mass Spectrometry-Based Study | Blood | Mouse | Cancer | Sharjah Institute for Medical Research | AU |
ST003143 | AN005157 | Mitochondrial complex I promotes kidney cancer metastasis | Kidney | Human | Cancer | University of Texas Southwestern Medical Center at Dallas | Normalized Abundance |
ST003143 | AN005157 | Mitochondrial complex I promotes kidney cancer metastasis | Tumor cells | Human | Cancer | University of Texas Southwestern Medical Center at Dallas | Normalized Abundance |
ST003143 | AN005158 | Mitochondrial complex I promotes kidney cancer metastasis | Kidney | Human | Cancer | University of Texas Southwestern Medical Center at Dallas | Normalized Abundance |
ST003143 | AN005158 | Mitochondrial complex I promotes kidney cancer metastasis | Tumor cells | Human | Cancer | University of Texas Southwestern Medical Center at Dallas | Normalized Abundance |
ST000148 | AN000235 | A549 13C-labeled Cell Study | Epithelial cells | Human | Cancer | University of Kentucky | normalized corrected peak area |
ST000016 | AN000033 | NPM-ALK metabolic regulation | Lymphoma cells | Human | University of Michigan | Peak area | |
ST000142 | AN000225 | H1299 13C-labeled Cell Study | Lung | Human | Cancer | University of Kentucky | Peak area |
ST001218 | AN002031 | Wild type versus TRACK Mice on regular chow and Vitamin A deprived diet | Kidney | Mouse | Cancer | weill cornell medicine | Peak area |
ST001265 | AN002102 | Comparative metabolomics of MCF-7 breast cancer cells using different extraction solvents assessed by mass spectroscopy | Breast cancer cells | Human | Cancer | Sharjah Institute for Medical Research | Peak area |
ST002876 | AN004713 | High Level Expression of NSD2 Creates a Metabolic Dependency in Multiple Myeloma | B-cells | Human | Cancer | University of Florida | Peak area |
ST000421 | AN000663 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
ST000421 | AN000664 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
ST000421 | AN000665 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
ST000422 | AN000667 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
ST000422 | AN000668 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
ST000422 | AN000669 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
ST000045 | AN000075 | Plasma metabolomics: Comparison of non-diabetic controls with T1D patients | Blood | Human | Mayo Clinic | Raw MS Intensities | |
ST000046 | AN000076 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
ST000046 | AN000077 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
ST000046 | AN000078 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
ST000046 | AN000079 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
ST000047 | AN000080 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
ST000047 | AN000081 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
ST000047 | AN000082 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
ST000047 | AN000083 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
ST002231 | AN003641 | Metabolomics Analysis of HOG-EV and HOG-R132H Cells with and without BAY 2402234 Treatment | Cultured cells | Human | Cancer | UT Southwestern Medical Center | TIC-Corrected Peak Area |
ST000588 | AN000903 | Metabolomics of Saliva in Decompensated Heart Failure | Saliva | Human | Heart disease | Mayo Clinic | uM |
ST002082 | AN003397 | Predicting dying: a study of the metabolic changes and the dying process in patients with lung cancer | Urine | Human | Cancer | University of Liverpool Institute of Life Course & Medical Sciences | Values are raw peak area |